SUMMARY 5-Fluorouracil (5-FU) requires activation to the metabolites FdUMP and FUTP for its cytotoxic effect. This activation involves the intracellular enzymes uridine and thymidine phosphorylase. We have assayed the levels of these enzymes in colorectal and gastric cancers and have shown that, in the majority of cases, the enzyme levels were higher than in the adjacent normal mucosa. It is suggested that, while the ratio tumour/normal mucosa enzyme activity may give some indication of the relative toxicity of 5-FU in these tissues, the absolute activities of the phosphorylases in tumour tissue could give a better indication of tumour responsiveness. It is generally accepted that 5-FU itself has no direct cytotoxic activity but exerts its influence via its active metabolites 5-fluorodeoxyuridine-5'-monophosphate (FdUMP) which inhibits thymidylate synthetase activity thereby starving cells of TMP for DNA synthesis4 and 5-fluorouridine-5'-triphosphate (FUTP) which becomes incorporated into RNA and seems to affect both RNA maturation and DNA synthesis. Recent evidence would seem to suggest that possibly it is the second metabolite FUTP which may exert the major cytotoxic influence.5 6 As nucleotides do not readily cross cell membranes it is logical to assume that activation will occur intracellularly and that the effect of the metabolites will be restricted to the activating cell.
SUMMARY 5-Fluorouracil (5-FU) requires activation to the metabolites FdUMP and FUTP for its cytotoxic effect. This activation involves the intracellular enzymes uridine and thymidine phosphorylase. We have assayed the levels of these enzymes in colorectal and gastric cancers and have shown that, in the majority of cases, the enzyme levels were higher than in the adjacent normal mucosa. It is suggested that, while the ratio tumour/normal mucosa enzyme activity may give some indication of the relative toxicity of 5-FU in these tissues, the absolute activities of the phosphorylases in tumour tissue could give a better indication of tumour responsiveness. 5 -Fluorouracil (5-FU) remains the most effective of the currently available cytotoxic drugs for use against gastrointestinal tumours.l-3 Only 20% of patients with advanced cancer, however, show a definitive response which, although short-lived, does double the mean survival time of responders over non-responders or untreated patients. As such a small percentage of patients respond to 5-FU therapy it is clearly desirable to identify those patients who are likely to respond and to avoid unnecessary treatment in the remainder.
It is generally accepted that 5-FU itself has no direct cytotoxic activity but exerts its influence via its active metabolites 5-fluorodeoxyuridine-5'-monophosphate (FdUMP) which inhibits thymidylate synthetase activity thereby starving cells of TMP for DNA synthesis4 and 5-fluorouridine-5'-triphosphate (FUTP) which becomes incorporated into RNA and seems to affect both RNA maturation and DNA synthesis. Recent evidence would seem to suggest that possibly it is the second metabolite FUTP which may exert the major cytotoxic influence.5 6 As nucleotides do not readily cross cell membranes it is logical to assume that activation will occur intracellularly and that the effect of the metabolites will be restricted to the activating cell.
Much work has been published attempting to relate cellular sensitivity to 5-FU with the activity of enzymes thought to be involved in this activation process.7-10 The enzymes uridine phosphorylase, uridine kinase, uracil phosphoribosyl transferase, and the nucleotide kinases are common for the activation of 5-FU to both FdUMP and FUTP Received for publication 1 March 1982 ( Figure) . Thymidine phosphorylase and kinase and ribonucleotide reductase are more exclusively involved with activation to FdUMP. In this study we have assayed the levels of two of these activating enzymes uridine and thymidine phosphorylase within gastrointestinal mucosa and within matched samples of gastrointestinal carcinomas to determine whether the enzymes display a markedly different activity in the two tissues.
Methods

MATERIALS
Nucleosides were obtained from Sigma Chemical Co. Ltd. and 5-FU sodium salt from Hoffman La Roche. HPLC grade solvents from BDH or Fisons were used where indicated. All other reagents were of analytical grade obtained from BDH.
PATIENTS AND PATIENT SAMPLING
Twenty eight patients were included in the
5-fluorodeoxyuridine -. (1) thymidine phosphorylase; (2) uridine phosphorylase; (3) uracilphosphoribosyltransferase; (4) uridine kinase; (5) thymidine kinase; (6) , (7) experiments, 15 males and 13 females. All were patients with gastrointestinal tumours and were subjected to surgical excision of the primary tumour. Fifteen of the patients received 5-FU from one to four days before operation and at this time most (13 patients) had the-plasma pharmacokinetics of the drug monitored. The remaining 13 patients received no 5-FU. Tumour site was divided as follows: gastric, three; right colon, five; colon, seven; rectum, 13.
After the specimen was removed a piece of tumour (0.5 g minimum) and of normal mucosa (if possible no closer than 10 cm to the tumour) were randomly cut from it as soon as possible, frozen in liquid nitrogen, and stored at -70°C for subsequent analysis.
The There was no significant correlation between the age of the patient and the tissue levels of deoxyuridine phosphorylase or uridine phosphorylase in normal or tumour tissue nor when the tumour/normal mucosal ratio was calculated. There was, however, a degree of positive correlation between increasing age and thymidine phosphorylase in normal mucosa (Rs=0.478, p<O0O2) but not tumour tissue.
EFFECT OF SEX OF PATIENT
There was no statistical difference between the results obtained for males and females with regard to any of the phosphorylase activities measured in either tumour or normal mucosa, although females did display a slightly higher average activity than males in both tissues and with all three phosphorylases. The range of phosphorylase levels in normal and cancerous tissue is shown in Table 1 .
EFFECT OF MUCOSAL SITE
In normal mucosa deoxyuridine phosphorylase was This pattern of correlation in the normal mucosa was mirrored by the tumour/normal mucosa ratio (Table 2) in which there was good correlation between thymidine and deoxyuridine (Rs=0.787, p<0-02) but poorer correlation between thymidine and uridine (Rs=0.354, p<O0 1) and between uridine and deoxyuridine (Rs=0.379, p<0.1). The above would seem to indicate that possibly the ratio is more dependent on changes in the normal mucosa activity of these enzymes than on their activity in tumour tissue and, in fact, when rank correlations were performed of tumour vs ratio and normal mucosa vs ratio it was found that the correlation was 
always better with normal mucosa than with tumour (thymidine-tumour, Rs=0400; normal mucosa, Rs=0*436; deoxyuridine-tumour, Rs=0*478; normal mucosa, Rs = 0677; uridine-tumour, Rs=0296; normal mucosa, Rs=0.709).
Discussion
At this stage there is not enough clinical follow-up information on the 28 patients in this study to allow for any conclusions to be reached about the possible usefulness of pyrimidine nucleoside phosphorylase activity as a predictor of tumour response to 5-FU. Nor has the study revealed a clearly defined subgroup of patients with greatly increased or decreased activity of any of the enzymes measured in either tissue or in the tumour/normal mucosa ratio which could be postulated to correspond with responder or non-responder status. It would seem likely, in view of the fact that equilibrium for these enzymes favour nucleoside formation, that a higher enzyme activity in the presence of sufficient pentose-1-phosphate could correlate with enhanced tumour sensitivity. 10 It is interesting to note that tumour site does not seem to affect the activity of the pyrimidine nucleoside phosphorylases. The fact that tumour levels of the enzymes are higher than in normal mucosa may be an indication that the tumours are growing faster or capable of more rapid replication than the surrounding mucosa. Thymidine phosphorylase tissue distribution studies would seem to indicate that an increased relative growth rate is associated with increased activity of the phosphorylase but it is not clear whether this is due to an increase in the 'salvage' function or to the catabolic activity acting as a damper on the increase in thymidine concentration (thymidine is known to inhibit cell growth at high concentrations).
A number of studies have demonstrated that tissue from a variety of sources contains more than one pyrimidine nucleoside phosphorylase12-14 and that the spectrum of activity with the different substrates (uridine, deoxyuridine, and thymidine) varies with the differing enzyme or isoenzyme. The present study would seem to indicate that there is possibly more than one enzyme involved in the present system. Yamada12 has suggested that thymidine phosphorylase from rat liver will display activity with both thymidine and deoxyuridine, while the uridine phosphorylases can use all three substrates. If this is so in the human intestine, then it would seem from the correlation data presented here that thymidine phosphorylase and uridine phosphorylase are making a different contribution to total pyrimidine nucleoside phosphorylase activity in tumour and normal mucosa. In the present study it appears that the predominant enzyme in tumour tissue is probably uridine phosphorylase because there was enhanced activity against all three substrates. In normal mucosa, however, the major contribution would seem to be from thymidine phosphorylase, as there was only good correlation between the activities with thymidine and deoxyuridine as substrate.
When the activity of pyrimidine nucleoside phosphorylase in tumour and in normal mucosa is correlated with the ratio of activities in the two tissues we found that the negative correlation with normal mucosa was always slightly better than the positive correlation with tumour activity. This was particularly so when the substrate was uridine or deoxyuridine. From this it might be concluded that in the case of pyrimidine nucleoside phosphorylase the tumour/normal mucosa ratio is more dependent on differences in the activity of the enzyme in normal mucosa than in tumour and hence that, while the ratio may be a useful indicator of the relative potential toxicity of 5-FU to tumour and normal mucosa, the absolute tumour activity might be a better indicator of tumour responsiveness. 
